Replies to post #114540 on Biotech Values

[mcbio]

still looking at arry which i know you follow but to me this company seems like it has lots of products but there all maybe 2nd to 3rd best in class to me?

As I've said, I think the MEK inhibitors are a big key for ARRY right now. If the data is positive on one or both of their MEK inhibitors later this year, then I think ARRY will be in great shape. If the data is not great, I may consider moving on (depending on where the share price is of course).

mcbio anythoughts on amrn??? i know you dont like big binary events but this company seems to have a blockbuster and is willing to partner very soon. i am a buyer.

Yep, I won't be touching it in front of the second Phase 3 trial results. ; ) If negative, I think you can safely expect the stock to drop some. The only question, of course, is how much? Could be a buying opportunity if results are negative and the stock drops too much as it looks to me like they still have a nice drug based on the initial results in a different patient population.